The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment

Journal of the Neurological Sciences

Volumn 305, Issue 1-2, 2011, Pages 92-96

  Fei, Ma ^a   Jianghua, Wang ^a   Rujuan, Miao ^a   Wei, Zhao ^a   Qian, Wang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

A ; A 42 A 40 ratio; Alzheimer's disease; Cohort study; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PROSPECTIVE STUDIES;

EID: 79955700546     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.03.005     Document Type: Article

References (33)

1. Levey Allan, Lah James, Goldstein Felicia, Steenland Kyle, Bliwise Donald. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther 2006;28:991-1001.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94. (Pubitemid 39222988)
3. Selkoe DJ. Alzheimer's disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004;140:627-38.
4. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994;17:489-517. (Pubitemid 24117040)
5. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM. Increased plasma amyloid β protein 1-42 levels in Down's syndrome. Neurosci Lett 1998;241:13-6. (Pubitemid 28079022)
6. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-70. (Pubitemid 26296755)
7. Tokuda Takahiko, Fukushima Tetsuro, Ikeda Shu-Ich, Sekijima Yoshiki, Shoji Shin'Ichi, Yanagisawa Nobuo, et al. Plasma levels of amyloid β proteins Aβ1-40 and Aβ1-42(3) are elevated in Down's Syndrome. Ann Neurol 1997;41:271-3.
8. Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The β APP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(3). Neurology 1997;48:741-5.
9. Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001;301:199-203. (Pubitemid 32226434)
10. Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H. Relationship between ApoE genotype and CSF beta-amyloid(1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000;21:735-40.
11. Stefani Alessandro, Martorana Alessandro, Bernardini Sergio, Panella Marta, Mercati Flavio, Orlacchio Antonio, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 2006;251:124-8.
12. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-80.
13. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol 2007;66:264-71.
14. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma abeta42/abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64: 354-62. (Pubitemid 46425689)
15. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006;5:655-60.
16. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92. (Pubitemid 33143977)
17. Association American Psychiatric. Diagnostic and statistical manual of mental disorders. ed 3, revised. Arlington: American Psychiatric Association; 1987.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
19. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology 1993;43:250-60.
20. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999;53:902-5. (Pubitemid 29442100)
21. Brun A, Englund E, Gustafson L, Passant U, Mann D, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994;57:416-8. (Pubitemid 24118135)
22. World Health Organization Collaborating Center for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index. Oslo, Norway: World Health Organization; 1997.
23. Vanderstichele H, Blennow K, D'Heuvaert N, Buyse M, Wallin A, Andreasen N, et al. Development of a specific diagnostic test for measurement of β-amyloid (1-42) in CSF, in progress in Alzheimer's and Parkinson's diseases. Alzheimers Park Dis 1998:773-8.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43. (Pubitemid 13033817)
25. Perkins NJ, Schisterman EF. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-5.
26. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
27. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R. Mild cognitive mpairment: directions for future research. Neurology 2003;61:438-44. (Pubitemid 37025357)
28. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, et al. CSF tau protein phosphorilated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-9. (Pubitemid 34920005)
29. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-34. (Pubitemid 35340483)
30. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-71. (Pubitemid 28283219)
31. Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, et al. Platelet Amyloid Precursor Protein Abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study. Arch Neurol 2003;60:1740-4. (Pubitemid 37521629)
32. Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, et al. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun 2004;319:733-7. (Pubitemid 38739382)
33. Blennow K. Hampel H.CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13. (Pubitemid 37162569)